New blood treatment could save trauma patients faster
NCT ID NCT07218185
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new shelf-stable blood product (IFC) works faster than the standard cryoprecipitate to stop severe bleeding in trauma patients. About 320 adults with traumatic injuries and low fibrinogen levels will be enrolled. The goal is to see if IFC can be given more quickly and correct bleeding problems sooner, potentially improving survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FUNCTIONAL HYPOFIBRINOGENEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anschutz Medical Center, University of Colorado
Aurora, Colorado, 80045, United States
-
Barnes Jewish Hospital, Washington University of Saint Louis
St Louis, Missouri, 63110, United States
-
R Adams Cowley Shock Trauma Center, University of Maryland
Baltimore, Maryland, 21201, United States
-
Ryder Trauma Center/Jackson Memorial Hospital, University of Miami
Miami, Florida, 33136, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new dissolvable dressing stop surgical bleeding faster?
- Can early blood transfusions save more trauma victims?
- Medical glue vs. internal bleeding: a new hope?
- Can a single stitch beat a double closure for TAVI patients?
- A facelift without the bruising? tranexamic acid put to the test.
- Which broken bones lead to Life-Threatening bleeding? a new study aims to find out